浙江尖峰亦恩生物科技

Zhejiang Jianfeng Yien Biotech is a China-based biotechnology company specializing in the development and industrial-scale manufacturing of recombinant protein vaccines and therapeutic biologics. Established as a strategic joint venture involving the Jianfeng Group, the company operates a large-scale production base in Jinhua, Zhejiang, designed to meet international GMP standards. The firm's core capabilities include high-density mammalian cell culture and advanced protein purification processes. Its most prominent achievement is the industrialization of a recombinant subunit COVID-19 vaccine, which was developed to address global pandemic needs. Beyond its internal pipeline, Jianfeng Yien provides CDMO services to facilitate the clinical and commercial production of biologics for domestic and international partners.